{"id":"folfox-1d","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFOX is a combination chemotherapy regimen where 5-fluorouracil (5-FU) inhibits thymidylate synthase to disrupt DNA synthesis, leucovorin enhances 5-FU activity by stabilizing its binding to the enzyme, and oxaliplatin is a platinum agent that forms DNA crosslinks. The '1d' designation likely refers to a specific dosing schedule variant of the standard FOLFOX regimen.","oneSentence":"FOLFOX 1d is a chemotherapy regimen combining 5-fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:14.116Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (likely primary indication based on FOLFOX standard use)"}]},"trialDetails":[{"nctId":"NCT06917079","phase":"PHASE1","title":"BBO-11818 in Adult Subjects With KRAS Mutant Cancer","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2025-03-31","conditions":"Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":387},{"nctId":"NCT06179160","phase":"PHASE1","title":"A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2024-01-04","conditions":"Solid Tumors","enrollment":710},{"nctId":"NCT04430738","phase":"PHASE2","title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-09-15","conditions":"Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma","enrollment":40},{"nctId":"NCT07318805","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-16","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer","enrollment":260},{"nctId":"NCT06576037","phase":"PHASE1","title":"Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-31","conditions":"Solid Tumor","enrollment":128},{"nctId":"NCT05476432","phase":"PHASE3","title":"HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-07-26","conditions":"Hepatocellular Carcinoma","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FOLFOX 1d","genericName":"FOLFOX 1d","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFOX 1d is a chemotherapy regimen combining 5-fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells. Used for Colorectal cancer (likely primary indication based on FOLFOX standard use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}